{{author}}{{author}}{{($index > metadata.AuthorsAndEtalArray.length-1) ? ',' : '.'}}

Lindsay Armstrong-Buisseret, Clare Brittain, Joe Kai, Miruna David, Jocelyn Anstey Watkins, Mara Ozolins, Louise Jackson, Zainab Abdali, Trish Hepburn, Frances Griffiths, Alan Montgomery, Jane Daniels, Alice Manley, Gillian Dean & Jonathan DC Ross.

Lindsay Armstrong-Buisseret ¹, Clare Brittain ¹, Joe Kai ², Miruna David ³, Jocelyn Anstey Watkins ⁴, Mara Ozolins ¹, Louise Jackson ⁵, Zainab Abdali ⁵, Trish Hepburn ¹, Frances Griffiths ^4,6, Alan Montgomery ¹, Jane Daniels ¹, Alice Manley ⁷, Gillian Dean ⁸, Jonathan DC Ross ^7,*

¹ Nottingham Clinical Trials Unit, University of Nottingham, Nottingham, UK
² Division of Primary Care, School of Medicine, University of Nottingham, Nottingham, UK
³ Clinical Microbiology, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
⁴ Division of Health Sciences, Warwick Medical School, University of Warwick, Coventry, UK
⁵ Health Economics Unit, Institute of Applied Health Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK
⁶ Centre for Health Policy, University of the Witwatersrand, Johannesburg, South Africa
⁷ Department of Genitourinary Medicine, Whittall Street Clinic, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
⁸ Elton John Research Centre, Brighton, UK
^* Corresponding author Email: jonathan.ross@uhb.nhs.uk

Declared competing interests of authors: Lindsay Armstrong-Buisseret reports ownership of shares in AstraZeneca plc (Cambridge, UK). Trish Hepburn reports ownership of shares in AstraZeneca plc. Alan Montgomery reports grants from the National Institute for Health Research (NIHR) during the conduct of the trial, membership of the NIHR Health Technology Assessment (HTA) programme Clinical Evaluation and Trials Funding Committee (2016–present) and that Nottingham Clinical Trials Unit (CTU) receives CTU funding from NIHR. Jane Daniels reports membership of the NIHR CTU Standing Advisory Group (2016–22). Jonathan DC Ross reports personal fees from GlaxoSmithKline plc (Brentford, UK), Mycovia Pharmaceuticals, Inc. (Durham, NC, USA) and Nabriva Therapeutics (Dublin, Ireland); reports ownership of shares in GlaxoSmithKline plc and AstraZeneca plc; is author of the UK and European Guidelines on Pelvic Inflammatory Disease; is a member of the European Sexually Transmitted Infections Guidelines Editorial Board (2000–present); and is a member of the NIHR Funding Committee (HTA programme, 2016–present). He is a member of the NIHR HTA and Efficacy and Mechanism Evaluation Editorial Board and is associate editor of the Sexually Transmitted Infections journal. He is an officer of the International Union against Sexually Transmitted Infections (treasurer) and a charity trustee of the Sexually Transmitted Infections Research Foundation.